The letters TTR getting knocked down by a heart from the aura of AMVUTTRA The letters TTR getting knocked down by a heart from the aura of AMVUTTRA

Strength in Silencing

The first and only treatment for both ATTR‑CM and hATTR‑PN, AMVUTTRA® suppresses TTR* production at the source.1‑4

Explore the data

*The primary source of TTR production is the liver.5

Heart icon

Explore the efficacy data for ATTR‑CM

HELIOS-B Efficacy
Neurologic icon

Explore the efficacy data for hATTR‑PN

HELIOS-A Efficacy
DNA Helix icon

Explore AMVUTTRA’s mechanism of action

How AMVUTTRA Works
Syringe dosing icon

Learn about the dosing and administration of AMVUTTRA

Dosing & Administration
Patient clipboard icon

Learn how to get your patients started with AMVUTTRA

Get Started With AMVUTTRA
Patient support icon

Learn about patient support services

Access & Support

Backed by real world experience and recommended by Guidelines

ACC Concise
Clinical Guidance

Includes AMVUTTRA as a first-line treatment option for ATTR-CM6
2025

ESC Guidelines for the management of heart failure

CLASS 1 RECOMMENDATION, LEVEL A
AMVUTTRA is recommended as a first-line treatment option for patients with ATTR-CM7
Level of evidence A applies to the shared recommendation, supported by studies of vutrisiran, tafamidis, and acoramidis.
2026
Over 14,000 Over 14,000

Over 14,000 patients treated with AMVUTTRA worldwide8*

*Estimates reflect worldwide commercial use of AMVUTTRA for ATTR-CM and hATTR-PN as of May 2026.

ACC=American College of Cardiology; ATTR-CM=cardiomyopathy of transthyretin-mediated amyloidosis; ESC=European Society of Cardiology; hATTR-PN=polyneuropathy of hereditary transthyretin-mediated amyloidosis; TTR=transthyretin.

Stay informed

Receive more information about AMVUTTRA.

Connect with us

Find a treatment center

Locate a treatment center closest to your patients.

View the directory

UP NEXT: ATTR disease overview Up Next icon

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

In a study of patients with hATTR-PN, the most common adverse reactions that occurred in patients treated with AMVUTTRA were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).

In a study of patients with ATTR-CM, no new safety issues were identified.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Indications

AMVUTTRA® (vutrisiran) is indicated for the treatment of the:

  • cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.
  • polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information .

References

  1. AMVUTTRA® Prescribing Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc.
  2. Fontana et al. N Engl J Med. 2025;392(1):33-44.
  3. Tomasoni et al. Front Cardiovasc Med. 2023;10:1154594.
  4. Williams et al. J Cardiothorac Vasc Anesth. 2024;38(7):1457-1459.
  5. Bezerra et al. Front Mol Neurosci. 2020;13:592644.
  6. Kittleson et al. J Am Coll Cardiol. 2026;87(5):549-565.
  7. Kober et al. Eur Heart J. 2026;47(32):4357-4374.
  8. Data on file. Alnylam Pharmaceuticals, Inc.